vs

Side-by-side financial comparison of LINKBANCORP, Inc. (LNKB) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $46.0M, roughly 1.6× LINKBANCORP, Inc.). On growth, LINKBANCORP, Inc. posted the faster year-over-year revenue change (7.3% vs -36.9%). LINKBANCORP, Inc. produced more free cash flow last quarter ($23.8M vs $-6.6M). Over the past eight quarters, LINKBANCORP, Inc.'s revenue compounded faster (6.6% CAGR vs -34.4%).

LINKBANCORP, Inc. is a US-based bank holding company that offers comprehensive retail and commercial banking services to individual consumers, small businesses, and mid-sized enterprises. Its core offerings include deposit accounts, lending products, wealth management solutions, and digital banking services, primarily serving customers across regional markets in Pennsylvania.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

LNKB vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.6× larger
MED
$75.1M
$46.0M
LNKB
Growing faster (revenue YoY)
LNKB
LNKB
+44.2% gap
LNKB
7.3%
-36.9%
MED
More free cash flow
LNKB
LNKB
$30.4M more FCF
LNKB
$23.8M
$-6.6M
MED
Faster 2-yr revenue CAGR
LNKB
LNKB
Annualised
LNKB
6.6%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LNKB
LNKB
MED
MED
Revenue
$46.0M
$75.1M
Net Profit
$2.9M
Gross Margin
69.4%
Operating Margin
8.5%
-10.4%
Net Margin
6.4%
Revenue YoY
7.3%
-36.9%
Net Profit YoY
-61.2%
EPS (diluted)
$0.08
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LNKB
LNKB
MED
MED
Q4 25
$46.0M
$75.1M
Q3 25
$44.8M
$89.4M
Q2 25
$42.3M
$105.6M
Q1 25
$53.4M
$115.7M
Q4 24
$42.9M
$119.0M
Q3 24
$42.9M
$140.2M
Q2 24
$41.3M
$168.6M
Q1 24
$40.5M
$174.7M
Net Profit
LNKB
LNKB
MED
MED
Q4 25
$2.9M
Q3 25
$7.8M
$-2.3M
Q2 25
$7.4M
$2.5M
Q1 25
$15.3M
$-772.0K
Q4 24
$7.6M
Q3 24
$7.1M
$1.1M
Q2 24
$5.8M
$-8.2M
Q1 24
$5.7M
$8.3M
Gross Margin
LNKB
LNKB
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
LNKB
LNKB
MED
MED
Q4 25
8.5%
-10.4%
Q3 25
22.3%
-4.6%
Q2 25
22.4%
-1.0%
Q1 25
36.0%
-1.1%
Q4 24
22.6%
0.6%
Q3 24
21.3%
1.5%
Q2 24
18.0%
-4.7%
Q1 24
18.1%
4.5%
Net Margin
LNKB
LNKB
MED
MED
Q4 25
6.4%
Q3 25
17.5%
-2.5%
Q2 25
17.5%
2.3%
Q1 25
28.7%
-0.7%
Q4 24
17.7%
Q3 24
16.5%
0.8%
Q2 24
14.1%
-4.8%
Q1 24
14.1%
4.8%
EPS (diluted)
LNKB
LNKB
MED
MED
Q4 25
$0.08
$-1.64
Q3 25
$0.21
$-0.21
Q2 25
$0.20
$0.22
Q1 25
$0.41
$-0.07
Q4 24
$0.21
$0.08
Q3 24
$0.19
$0.10
Q2 24
$0.16
$-0.75
Q1 24
$0.15
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LNKB
LNKB
MED
MED
Cash + ST InvestmentsLiquidity on hand
$52.3M
$167.3M
Total DebtLower is stronger
$177.3M
Stockholders' EquityBook value
$306.4M
$198.9M
Total Assets
$3.1B
$248.0M
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LNKB
LNKB
MED
MED
Q4 25
$52.3M
$167.3M
Q3 25
$194.2M
$173.5M
Q2 25
$155.1M
$162.7M
Q1 25
$220.2M
$164.6M
Q4 24
$166.1M
$162.3M
Q3 24
$191.2M
$170.0M
Q2 24
$181.7M
$163.5M
Q1 24
$172.3M
$156.4M
Total Debt
LNKB
LNKB
MED
MED
Q4 25
$177.3M
Q3 25
$102.3M
Q2 25
$102.3M
Q1 25
$102.7M
Q4 24
$112.5M
Q3 24
$102.4M
Q2 24
$102.3M
Q1 24
$102.2M
Stockholders' Equity
LNKB
LNKB
MED
MED
Q4 25
$306.4M
$198.9M
Q3 25
$305.5M
$214.7M
Q2 25
$298.0M
$216.0M
Q1 25
$294.1M
$211.0M
Q4 24
$280.2M
$210.1M
Q3 24
$277.4M
$207.3M
Q2 24
$271.4M
$205.3M
Q1 24
$268.2M
$211.0M
Total Assets
LNKB
LNKB
MED
MED
Q4 25
$3.1B
$248.0M
Q3 25
$3.1B
$268.2M
Q2 25
$2.9B
$269.3M
Q1 25
$2.9B
$280.0M
Q4 24
$2.9B
$284.2M
Q3 24
$2.9B
$291.2M
Q2 24
$2.9B
$293.5M
Q1 24
$2.8B
$302.8M
Debt / Equity
LNKB
LNKB
MED
MED
Q4 25
0.58×
Q3 25
0.33×
Q2 25
0.34×
Q1 25
0.35×
Q4 24
0.40×
Q3 24
0.37×
Q2 24
0.38×
Q1 24
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LNKB
LNKB
MED
MED
Operating Cash FlowLast quarter
$25.3M
$-5.3M
Free Cash FlowOCF − Capex
$23.8M
$-6.6M
FCF MarginFCF / Revenue
51.7%
-8.8%
Capex IntensityCapex / Revenue
3.2%
1.8%
Cash ConversionOCF / Net Profit
8.59×
TTM Free Cash FlowTrailing 4 quarters
$55.3M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LNKB
LNKB
MED
MED
Q4 25
$25.3M
$-5.3M
Q3 25
$23.6M
$12.1M
Q2 25
$6.3M
$-3.4M
Q1 25
$2.6M
$3.4M
Q4 24
$25.4M
$-4.9M
Q3 24
$14.0M
$9.1M
Q2 24
$6.4M
$13.1M
Q1 24
$-771.0K
$7.3M
Free Cash Flow
LNKB
LNKB
MED
MED
Q4 25
$23.8M
$-6.6M
Q3 25
$23.2M
$10.8M
Q2 25
$6.1M
$-4.8M
Q1 25
$2.2M
$1.9M
Q4 24
$22.6M
$-7.2M
Q3 24
$13.1M
$7.7M
Q2 24
$6.3M
$11.1M
Q1 24
$-1.2M
$5.4M
FCF Margin
LNKB
LNKB
MED
MED
Q4 25
51.7%
-8.8%
Q3 25
51.8%
12.0%
Q2 25
14.5%
-4.5%
Q1 25
4.2%
1.6%
Q4 24
52.6%
-6.1%
Q3 24
30.5%
5.5%
Q2 24
15.3%
6.6%
Q1 24
-3.0%
3.1%
Capex Intensity
LNKB
LNKB
MED
MED
Q4 25
3.2%
1.8%
Q3 25
0.8%
1.5%
Q2 25
0.4%
1.3%
Q1 25
0.7%
1.3%
Q4 24
6.7%
1.9%
Q3 24
2.1%
1.0%
Q2 24
0.1%
1.1%
Q1 24
1.1%
1.1%
Cash Conversion
LNKB
LNKB
MED
MED
Q4 25
8.59×
Q3 25
3.01×
Q2 25
0.85×
-1.36×
Q1 25
0.17×
Q4 24
3.35×
Q3 24
1.97×
8.04×
Q2 24
1.10×
Q1 24
-0.13×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons